Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23724052 | 0.99 | APEX1 (0.36) | APEX1SMN1; SMN2POLBMEN1KDM4A | |
| SCHEMBL1065475 | 0.99 | APEX1 (0.36) | APEX1SMN1; SMN2POLBMEN1KDM4A | |
| SCHEMBL1067864 | 0.98 | APEX1 (0.35) | APEX1SMN1; SMN2POLBMEN1KDM4A | |
| SCHEMBL28395116 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2POLBMEN1KDM4AMAPT | |
| SCHEMBL881399 | 0.87 | APEX1 (0.34) | APEX1SMN1; SMN2POLBGAAALDH1A1 | |
| SCHEMBL1069437 | 0.84 | SMN1; SMN2 (0.38) | APEX1SMN1; SMN2POLBMEN1KDM4A | |
| SCHEMBL6018477 | 0.84 | MEN1 (0.35) | SMN1; SMN2POLBMEN1KDM4AMAPT | |
| Bromide SCHEMBL5458775 | 0.84 | PTGS1 (0.39) | SMN1; SMN2POLBMEN1KDM4AMAPT | |
| Bromide SCHEMBL14843908 | 0.83 | MDM2 (0.39) | SMN1; SMN2POLBMEN1KDM4AMAPT | |
| SCHEMBL15137506 | 0.83 | POLB (0.32) | APEX1SMN1; SMN2POLBGAARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773750-B1 | FORMULATION AND METHOD OF PREPARATION | GE HEALTHCARE AS (NO) | 2022-04-20 | — | — | EP | disclosed |
| US-20210046195-A1 | FORMULATION AND METHOD OF PREPARATION | GE HEALTHCARE AS (NO) | 2021-02-18 | — | — | US | disclosed |
| EP-3773750-A1 | FORMULATION AND METHOD OF PREPARATION | GE Healthcare AS (NO) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019185607-A1 | FORMULATION AND METHOD OF PREPARATION | GE HEALTHCARE AS (NO) | 2019-10-03 | — | — | WO | disclosed |
| US-8529874-B2 | Peptide imaging agents | GE HEALTHCARE AS (NO) | 2013-09-10 | — | — | US | disclosed |
| EP-2146749-B1 | LABELLED HGF BINDING PEPTIDES FOR IMAGING | GE HEALTHCARE AS (NO) | 2012-03-28 | — | — | EP | disclosed |
| US-20110268660-A1 | METHOD FOR DETECTING DYSPLASIA | GE HEALTHCARE AS (NO) | 2011-11-03 | — | — | US | disclosed |
| EP-2326352-A2 | METHOD FOR DETECTING DYSPLASIA | GE Healthcare AS (NO) | 2011-06-01 | — | — | EP | disclosed |
| US-20100303727-A1 | OPTICAL IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100150843-A1 | PEPTIDE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-06-17 | — | — | US | disclosed |
| WO-2010018230-A2 | METHOD FOR DETECTING DYSPLASIA | GE HEALTHCARE AS (NO) | 2010-02-18 | — | — | WO | disclosed |
| EP-2148702-A2 | PENTAMETHINE CYANINE DYES CARRYING AT LEAST THREE SULFONIC ACID GROUPS | GE Healthcare AS (NO) | 2010-02-03 | — | — | EP | disclosed |
| EP-2146749-A2 | LABELLED HGF BINDING PEPTIDES FOR IMAGING | GE Healthcare AS (NO) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008139207-A2 | LABELLED HGF BINDING PEPTIDES FOR IMAGING | GE HEALTHCARE AS (NO) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139206-A2 | OPTICAL IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046195-A1 | FORMULATION AND METHOD OF PREPARATION | IAPP, LPXN, KIT | APEX1 4505/4885SMN1; SMN2 1549/4885POLB 4565/4885 |
| US-20100303727-A1 | OPTICAL IMAGING AGENTS | MSN, SIGLEC7, FABP7 | APEX1 3893/4885SMN1; SMN2 1617/4885POLB 4876/4885 |
| US-20100150843-A1 | PEPTIDE IMAGING AGENTS | VIP, RXFP1, GRPR | APEX1 3174/4885SMN1; SMN2 3361/4885POLB 3755/4885 |
| US-20110268660-A1 | METHOD FOR DETECTING DYSPLASIA | EGFR, ERBB2, ERBB3 | APEX1 3518/4885SMN1; SMN2 3877/4885POLB 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.